Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.

@article{Morishita2012DoAD,
  title={Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.},
  author={Kimberly A Morishita and Jaime Guzman and Peter Chira and Eyal Muscal and Andrew S. Zeft and Marisa S. Klein-Gitelman and Am{\'e}rica G Uribe and Leslie W. Abramson and Susanne M Benseler and Anne Eberhard and Kaleo Ede and Philip J. Hashkes and Aimee O. Hersh and Gloria C. Higgins and Lisa F Imundo and Lawrence Jung and Susan Kim and Daniel J. Kingsbury and Erica F. Lawson and Tzielan Chang Lee and Suzanne C Li and Daniel J. Lovell and Thomas R. Mason and Deborah McCurdy and Kathleen O'neil and Marilynn Punaro and Suzanne E. Ramsey and Andreas Otto Reiff and Margalit E. Rosenkranz and Kenneth Noel Schikler and Rosie Scuccimarri and Nora G. Singer and Anne M Stevens and Heather A van Mater and Dawn M. Wahezi and A J White and David A. Cabral},
  journal={The Journal of rheumatology},
  year={2012},
  volume={39 10},
  pages={
          2012-20
        }
}
OBJECTIVE To determine whether adult disease severity subclassification systems for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are concordant with the decision to treat pediatric patients with cyclophosphamide (CYC). METHODS We applied the European Vasculitis Study (EUVAS) and Wegener's Granulomatosis Etanercept Trial (WGET) disease severity subclassification systems to pediatric patients with AAV in A Registry for Childhood Vasculitis (ARChiVe). Modifications were made… CONTINUE READING
BETA